Gento-Fibrose Pulmonaire Program
Idiopathic Pulmonary Fibrosis (IPF)
PreclinicalActive
Key Facts
About Genoscience Pharma
Genoscience Pharma is a private, clinical-stage biotech innovating in oncology and fibrotic diseases by targeting lysosomal biology. Its lead asset, GNS561, is in clinical development for primary liver cancers, and the company has secured European funding for a program in idiopathic pulmonary fibrosis (IPF). The company leverages a novel scientific platform and has established key partnerships, such as an exclusive licensing deal with Genfit for GNS561 in oncology, to advance its pipeline.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |